New drug combo vs usual care for high-risk myeloma in first relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a powerful new two-drug combo (daratumumab plus teclistamab) works better than the usual three-drug combos for people with high-risk multiple myeloma that has come back after just one prior treatment. If you’re in first relapse with high-risk features, this study could offer a promising new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have only had one line of therapy for your multiple myeloma (for example, one round of induction, transplant, and maintenance counts as one).
- Your myeloma has returned or is not responding to your current treatment.
- Your myeloma is considered high-risk, either because of certain chromosome changes or because your first relapse happened within 2 years of starting treatment.
- You haven’t had daratumumab or isatuximab before, or if you did, it’s been more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
This trial tests a four-drug combination (daratumumab, cabozantinib, pomalidomide, and dexamethasone) for patients with multiple myeloma that is either not responding to initial treatment or has come back for the first time, especially if it is considered high-risk. The goal is to see if this new combination works better than standard options.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.